Ferring’s ADSTILADRIN Hits €70M in Year One, Validating Gene Therapy Market Growth

Published on Spencer Knight via LinkedIn

Ferring Pharmaceuticals has emerged as a commercial frontrunner in gene therapy with the successful U.S. launch of ADSTILADRIN. Within its first year, the bladder cancer therapy generated €70M (~$77M) in revenue, secured 99% insurance coverage, and achieved a 25-day average reimbursement turnaround.

A newly approved U.S. manufacturing facility also unlocked a $200M milestone payment from Royalty Pharma. Spencer Knight highlights this as an encouraging signal that gene therapy can succeed not just in trials, but in the real-world marketplace through scalable, reimbursable solutions.

Read the full post on LinkedIn:

👉 Spencer Knight: Ferring Pharmaceuticals’ gene therapy shows commercial viability

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.